Product Detailed Description

Liposomal dihydroquercetin 70% — High Bioavailability Antioxidant Supplement

Product Overview

liposomal Dihydroquercetin 70% is a premium-grade dietary supplement ingredient delivering dihydroquercetin in an advanced liposomal delivery system. Dihydroquercetin (DHQ), also known as taxifolin or distylin, is a naturally occurring flavanonol belonging to the flavonoid subclass of polyphenols. It is chemically characterized by the molecular formula C₁₅H₁₂O₇ and a molecular weight of 304.25 g/mol, with the IUPAC name (2R,3R)-3,3′,4′,5,7-pentahydroxyflavan-4-one.

Dihydroquercetin is a natural bioflavonoid with diverse biological activities, including antioxidant, anti-inflammatory, antibacterial, antiviral, and geroprotective effects. It is a taxifolin that has a (2R,3R)-configuration and is extracted from plants such as Siberian larch (Larix sibirica) and milk thistle. The compound is a dihydroflavonol with a molecular structure that distinguishes it from quercetin, conferring unique biological properties.

Why Liposomal Technology?

Conventional dihydroquercetin presents significant formulation challenges. The compound has low solubility and limited bioavailability, which have stimulated the development of nanotechnology-based delivery systems including nanoparticles, liposomes, hydrogels, nanofibers, nanoenzymes, and crystalline complexes. Nanotechnologies are the most efficient means for improving the solubility and bioavailability of dihydroquercetin.

Liposomal encapsulation provides three critical advantages:

1. Solubility and Stability Enhancement — The phospholipid bilayer significantly improves the solubility and stability of dihydroquercetin, protecting it from degradation during digestive transit and making it more dispersible in aqueous systems.

2. Enhanced Cellular Uptake — Liposomes fuse directly with intestinal cell membranes, facilitating efficient cellular delivery and bypassing passive diffusion limitations. Liposomal encapsulation has been shown to enhance the therapeutic efficacy of dihydroquercetin in various experimental models.

3. Superior Bioavailability — A comparative pharmacokinetic study in rats demonstrated that liposomal delivery significantly improves the oral bioavailability of dihydroquercetin compared to the parent compound. Nanometerizing dihydroquercetin into selenized liposomes achieved a relative bioavailability of 216.65%, significantly higher than dihydroquercetin suspensions and unmodified liposomes.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% dihydroquercetin by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Phospholipid bilayer encapsulation significantly improves solubility, stability, and bioavailability compared to conventional dihydroquercetin forms.

• Clinically Validated Bioavailability — Nanometerized dihydroquercetin in liposomal form achieved a relative bioavailability of 216.65% compared to suspensions in pharmacokinetic studies.

• Potent Antioxidant — Dihydroquercetin enhances antioxidant capacity by activating antioxidant enzymes including superoxide dismutase (SOD) and Glutathione peroxidase.

• Nrf2 Pathway Activation — Dihydroquercetin induces HO-1 and NQO1 expression through the Nrf2-dependent antioxidant pathway, upregulating phase II detoxifying enzymes.

• Vascular and Metabolic Support — Dihydroquercetin has demonstrated efficacy in clinical studies for obesity, prediabetes, and cardiovascular conditions.

• Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies have evaluated dihydroquercetin across a range of doses. A clinical study in men with idiopathic infertility administered 60 mg of dihydroquercetin twice daily for 90 days, with semen parameters evaluated every 30 days. For obesity and prediabetes, dihydroquercetin was administered as a dietary supplement at a dose of 100–200 mg/day for 3 months with treatment interruption for 1 month. A clinical study in chronic heart failure patients evaluated dihydroquercetin at 240 mg/day as a single dose or combined with arabinogalactan. For general antioxidant and vascular support, 100–200 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.